A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ataluren (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 16 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 16 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 26 Aug 2017 This study has been completed in Germany, according to the European Clinical Trials Database record.